Biosidus SA is a biotechnology company in Argentina in the last three decades has developed a global business in supplying high quality biopharmaceuticals territories in Asia, Africa, Eastern Europe and Latin America.
Biosidus SA has two manufacturing plants. The Almagro Plant, located in the Autonomous City of Buenos Aires, is dedicated to R & D and production of active pharmaceutical ingredients, with production capacity massive bacterial fermentation and cell culture. Operations aseptic filling, lyophilization and packaging are conducted in Bernal Plant, located on the outskirts of Buenos Aires.
Biosidus has a robust pipeline of therapeutic proteins in different stages of development.
The Company has developed innovative technology platforms in transgenic animals, gene therapy and biodiversity.
The manufacturing processes and new technologies developed by Biosidus are based on a solid intellectual property policy, which is an important competitive advantage in the stage of biosimilars.
With his outstanding career, Biosidus is destined to become a reliable supplier of biosimilars globally.
Biosidus SA
Constitution 4234 – C1254ABX Buenos Aires | Argentina
Tel .: +5411 4909 8000 – Fax +5411 4909 8055
Santiago Garcia Belmonte, president of Biosidus, discusses how global regulatory trends are driving change in the Argentinian biotech industry, as well the new direction his firm has taken over the…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in…
The Head of Viatris Latin America, Patrick Doyle, spoke to PharmaBoardroom about setting up the two-year old company’s Latam affiliate during the pandemic, the decision to focus on specific therapeutic…
Boehringer Ingelheim’s managing director for South America, Dirk van Niekerk, provides an overview of the healthcare climate in South America, the challenges tied to political and economic instability, future opportunities…
Dr Guillermo Chantada, incoming president-elect of the International Society of Paediatric Oncology (SIOP) highlights the progress of paediatric oncology in Latin America and gives a call to arms to the…
See our Cookie Privacy Policy Here
